🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

APx Acquisition Corp. I issues $446,000 promissory note to Bioceres

EditorEmilio Ghigini
Published 28/08/2024, 15:36
APXIU
-

In a recent development, APx Acquisition Corp. I ("APx"), a company classified under the "Blank Checks" sector, has entered into a significant financial agreement. On Monday, the company issued an unsecured promissory note in the principal amount of $446,000 to Bioceres LLC, an indirect shareholder of OmnigenicsAI Corp.

This promissory note, bearing an interest rate of 20% per annum, is set against the backdrop of APx's previously announced business combination with OmnigenicsAI Corp.

The note stipulates that the principal and any accrued interest will be due on the date APx completes its initial business combination, which is referred to as the Maturity Date. The terms of the note include standard default provisions, which could lead to immediate repayment obligations should certain events occur.

The issuance of the note is exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. The transaction is detailed in Exhibit 10.1 of the Current Report on Form 8-K filed by the company.

APx, incorporated in the Cayman Islands with its executive offices in Nashville, TN, has its securities listed on The NASDAQ Stock Market LLC. The company trades under the symbols APXIU for its units, APXI for its Class A Ordinary Shares, and APXIW for its warrants.

The company's decision to undertake this financial obligation is disclosed in accordance with SEC regulations, and the full details of the note are available for review in the attached exhibit of the SEC filing. This financial move by APx Acquisition Corp. I is based on a press release statement and is part of the company's broader strategy as it works towards its initial business combination.

InvestingPro Insights

As APx Acquisition Corp. I navigates through its financial strategies, including the issuance of a high-interest promissory note to Bioceres LLC, understanding the company's financial health and market position becomes crucial for investors. According to InvestingPro data, APx has a market capitalization of $115.25 million and a P/E ratio of 29.67 based on the last twelve months as of Q3 2023. Despite a challenging operating income of -$1.76 million in the same period, the company has managed to remain profitable, with a basic and diluted EPS from continuing operations at $0.4.

InvestingPro Tips highlight APx's current trading status near its 52-week high, which can be a double-edged sword for potential investors. The company's stock generally trades with low price volatility, which may appeal to those looking for stability in their investments. However, it's worth noting that APx's short-term obligations exceed its liquid assets, indicating potential liquidity risks. Additionally, APx does not pay a dividend to shareholders, which could influence the investment decisions of income-focused investors.

For investors seeking a more in-depth analysis, there are additional InvestingPro Tips available on InvestingPro, providing a comprehensive look at the company's financial metrics and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.